Physician profile
John Meadows
NPI 1245220193
$1,359.13
in general payments reported to CMS, 2019-2025
14 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.80 · 2022: $45.44 · 2023: $228 · 2024: $504 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.98 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $194.33 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $142.60 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $111.70 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $106.04 | 2024-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $102.14 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $62.61 | 2024-2025 | Ibsrela |
| Pfizer INC. | $49.15 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.70 | 2023-2024 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $30.59 | 2024 | Zeposia |
| Qol Medical, LLC | $27.01 | 2025 | Sucraid |
| Celltrion USA INC. | $22.31 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $19.09 | 2025 | |
| Lilly USA, LLC | $18.88 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.